Data / Drug companies / Lamivudine and zidovudine
Lamivudine and zidovudine: 8 companies and 10 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Lamivudine and zidovudine is listed in the FDA National Drug Code Directory by 8 companies, with 10 products in commercial distribution. 9 of the products (90.0%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet, film coated; tablet, and the newest product started marketing on April 17, 2020.
The request: Get every company that lists lamivudine and zidovudine in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 8
- Products
- 10
- Generic (ANDA) products
- 9 (90.0%)
- Application numbers
- 5
- Routes
- Oral
- Brand names
- Combivir
- openFDA record search
- api.fda.gov
Companies that list lamivudine and zidovudine
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Bryant Ranch Prepack | 2 | tablet, film coated; tablet | Generic drugs (ANDA) | August 30, 2018 |
| Camber Pharmaceuticals, Inc. | 2 | tablet, film coated | Generic drugs (ANDA) | September 18, 2015 |
| Aurobindo Pharma Limited | 1 | tablet, film coated | Generic drugs (ANDA) | May 5, 2017 |
| Exelan Pharmaceuticals Inc. | 1 | tablet, film coated | Generic drugs (ANDA) | April 29, 2015 |
| Macleods Pharmaceuticals Limited | 1 | tablet | Generic drugs (ANDA) | August 30, 2018 |
| PD-Rx Pharmaceuticals, Inc. | 1 | tablet, film coated | Generic drugs (ANDA) | September 18, 2015 |
| ViiV Healthcare Company | 1 | tablet, film coated | New drug applications (NDA) | October 19, 2010 |
| XLCare Pharmaceuticals, Inc. | 1 | tablet, film coated | Generic drugs (ANDA) | April 17, 2020 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 8 | 80% |
| Tablet | 2 | 20% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 9 | 90% |
| New drug applications (NDA) | 1 | 10% |
Pharmacologic classes
| Class | Products |
|---|---|
| Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor | 10 |
| Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor | 10 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.